Thrombotic and Bleeding Complications in Four Subpopulations of Patients with ET Defined by c-Mpl Protein Expression and PRV-1 mRNA Levels

Philipp L Goerttler(University of Freiburg), Heike-L. Pahl, Peter L. Johansson, R. Marchioli, J. L. Spivak, A. R. Moliterno, E März(University Hospital Ulm), J. Kutti, Björn Andréasson(NU Hospital Group)

FreiDok plus (Universitätsbibliothek Freiburg)

January 1, 2005

Cited by 0

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

|Journal of Clinical Oncology|2012|461

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

|Blood|2011|340

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

|Journal of Clinical Oncology|2011|244

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

|The Lancet|2023|194

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

|Blood|2014|153